Imunon (IMNN) vs NuCana (NCNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NuCana is the larger company by market cap ($3.6 million vs $3.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNN | NCNA |
|---|---|---|
| Share price | $0.5355 | $0.7495 |
| Market cap | $3.47M | $3.61M |
| 1-day change | -5.22% | +4.39% |
| EPS (TTM) | $-3.31 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-14.50M | — |
| 52-week high | $4.35 | $4.55 |
| 52-week low | $0.50 | $0.62 |
| Distance from 52-week high | -87.69% | -83.53% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +3074.60% | — |
| Average volume | 150.49K | 118.13K |
| Shares outstanding | 6.49M | 4.82M |
| Employees | 20 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About NuCana
NCNA stock →NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
IMNN vs NCNA FAQ
Which is bigger, Imunon or NuCana?
NuCana (NCNA) is larger, with a market capitalization of $3.61M compared with $3.47M for Imunon (IMNN).
Are Imunon and NuCana in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.